会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • COMPOSITE IMPLANTS FOR PROMOTING BONE REGENERATION AND AUGMENTATION AND METHODS FOR THEIR PREPARATION AND USE
    • 用于促进骨髓再生和补充的复合植入物及其制备和使用方法
    • US20080026032A1
    • 2008-01-31
    • US11829111
    • 2007-07-27
    • Yuval ZUBERYArie GoldlustThomas BayerEran Nir
    • Yuval ZUBERYArie GoldlustThomas BayerEran Nir
    • A61F2/00A61K38/00A61P19/00
    • A61L27/56A61L27/48C08L89/06
    • Collagen based matrices cross-linked by a reducing sugar(s) are used for preparing composite matrices, implants and scaffolds. The composite matrices may have at least two layers including reducing sugar cross-linked collagen matrices of different densities. The composite matrices may be used in bone regeneration and/or augmentation applications. Scaffolds including glycated and/or reducing sugar cross-linked collagen exhibit improved support for cell proliferation and/or growth and/or differentiation. The denser collagen matrix of the composite matrices may have a dual effect initially functioning as a cell barrier and later functioning as an ossification supporting layer. The composite matrices, implants and scaffolds may be prepared using different collagen types and collagen mixtures and by cross-linking the collagen(s) using a reducing sugar or a mixture of reducing sugars. The composite matrices, implants and scaffolds may include additives and/or living cells.
    • 用还原糖交联的基于胶原的基质用于制备复合基质,植入物和支架。 复合基质可以具有至少两层,包括不同密度的还原糖交联的胶原基质。 复合基质可用于骨再生和/或增强应用。 包括糖基化和/或还原糖交联胶原的支架显示改善的对细胞增殖和/或生长和/或分化的支持。 复合基质的更密集的胶原基质可能具有起初作为细胞屏障起作用的双重作用,并且此后作为骨化支持层起作用。 复合基质,植入物和支架可以使用不同的胶原类型和胶原混合物和使用还原糖或还原糖的混合物交联胶原来制备。 复合基质,植入物和支架可以包括添加剂和/或活细胞。
    • 5. 发明申请
    • MONOCLONAL ANTIBODIES TARGETING AMYLOID BETA OLIGOMERS
    • 单克隆抗体靶向AMYLOID BETA寡聚体
    • US20130295095A1
    • 2013-11-07
    • US13701758
    • 2011-06-03
    • Thomas BayerOliver WirthsHenrik MartensChristian Erck
    • Thomas BayerOliver WirthsHenrik MartensChristian Erck
    • C07K16/18
    • C07K16/18A61K2039/505C07K2317/32C07K2317/33C07K2317/76
    • The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated Aβ starting with pyroglutamate (AβρE), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing Aβ oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056. Further, the invention provides a method of inhibiting the formation or the seeding effect of said AβρE oligomers, and a method for identifying agents useful in the treatment and/or prevention of an amyloid-related disorder as well as methods of diagnosing a subject suspected of suffering from a disease associated with amyloidogenesis and/or amyloid plaque formation and to methods of monitoring the efficacy of a treatment of a disease associated with amyloidogenesis and/or amyloid-plaque formation characterized by the presence of Aβ oligomers in a subject.
    • 本发明涉及能够特异性识别由焦谷氨酸(AbetarhoE)开始的N-末端截短的Abeta的可溶性低聚物,包含其的药物组合物及其各自的治疗用途的结合分子。 特别地,本发明涉及能够特异性识别Aβ寡聚体的抗体分子,其中所述抗体结合和/或检测由DSM AC-C3056沉积的抗体PG3-38 9D5H6结合和/或检测的表位。 此外,本发明提供抑制所述AbetarhoE寡聚体的形成或播种作用的方法,以及用于鉴定可用于治疗和/或预防淀粉样蛋白相关病症的药剂的方法以及诊断疑似患者的方法 患有与淀粉样变性和/或淀粉样蛋白斑形成相关的疾病,以及监测治疗与淀粉样变性和/或淀粉样蛋白斑形成有关的疾病的功效的方法,其特征在于受试者中存在Aβ寡聚体。